Conference
Abstract A022: The use of LN status on developing prognostic gene signatures for ER+ breast cancer
Abstract
Abstract
Introduction: Estrogen Receptor (ER) positive Breast Cancers account for approximately 70% of all breast cancers and have a better prognosis than ER- breast cancer. These patients are amenable to endocrine treatment, including tamoxifen, which eliminates recurrence in a large group of patients, but approximately 30% will relapse within 15 years of diagnosis. The most important predictor of recurrence in ER+ breast …
Authors
Cockburn JG; Hallett RM; Hassell JA; Bane A
Volume
11
Pagination
pp. a022-a022
Publisher
American Association for Cancer Research (AACR)
Publication Date
October 1, 2013
DOI
10.1158/1557-3125.advbc-a022
Conference proceedings
Molecular Cancer Research
Issue
10_Supplement
ISSN
1541-7786